Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC). EGF104900 study suggested that among patients who experienced progression on prior trastuzumab‐containing regimens, lapatinib plus trastuzumab had better effects than trastuzumab alone. However, no...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Xie, Yizhao, Ge, Rui, Sang, Die, Luo, Ting, Li, Wei, Ji, Xuening, Yuan, Peng, Wang, Biyun
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7196046/
https://ncbi.nlm.nih.gov/pubmed/32108439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2943
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars